8-K: Orthofix Appoints Julie Andrews as New Chief Financial Officer

Orthofix Medical Inc. has appointed Julie Andrews as its new Chief Financial Officer, effective January 15, 2024.

Summary

• Orthofix Medical Inc. has appointed Julie Andrews as its new Chief Financial Officer, effective January 15, 2024.
• Ms. Andrews brings over 25 years of experience, primarily in the medical device sector, and previously served as CFO for Smart Wires Technology and Senior Vice President, Global Finance for Wright Medical Group.
• As an inducement, Ms. Andrews received performance-based restricted stock units for 65,934 shares, time-based restricted stock units for 32,967 shares, and stock options to purchase 76,878 shares.
• The performance-based units vest after three years based on the company's total stockholder return relative to a peer group index.
• Time-based units vest in equal tranches over three years.
• Stock options vest based on service and performance criteria, including a share price target of 150% of the grant date price over a one-month period.
• Ms. Andrews also has a Change in Control and Severance Agreement, which provides severance payments and benefits upon certain terminations of employment.
• The severance package includes a cash payment equal to 1.0 times her annual base salary and target bonus, plus $12,500 for outplacement services, which increases to 1.5 times if termination occurs within 24 months of a change in control.
• She will also receive up to 12 months of COBRA premium reimbursements.

Sentiment

Score: 8

Explanation: The document reflects a positive sentiment due to the appointment of an experienced CFO and the details of her compensation package. The language used is professional and optimistic about the future.

Positives

• The appointment of Julie Andrews brings a seasoned executive with over 25 years of experience in the medical device sector.
• The inducement package, including stock options and restricted stock units, aligns Ms. Andrews' interests with those of the shareholders.
• The severance agreement provides financial security and encourages her long-term commitment to the company.
• The change in control provisions in the severance agreement provide additional protection for Ms. Andrews.

Risks

• The performance-based vesting of stock units is contingent on the company's total stockholder return relative to a peer group index, which may not be achieved.
• The stock options vest based on a 150% share price target, which may not be reached.
• The company's obligation to pay severance and COBRA reimbursements is conditional upon Ms. Andrews signing a release of claims.

Future Outlook

The company expects Ms. Andrews to be a great partner to the leadership team as they continue to focus on developing growth opportunities that result in sustainable shareholder value. The company also looks for opportunities to improve performance while accelerating the business.

Management Comments

• Massimo Calafiore, President and Chief Executive Officer of Orthofix, stated, 'I am excited to welcome Julie to the Orthofix team. With more than 25 years of leadership experience predominately in the medical device sector, I am confident she will be a great partner to me and the leadership team as we continue to focus on developing growth opportunities that result in sustainable shareholder value.'
• Julie Andrews stated, 'I am pleased to be joining Orthofix and would like to thank Geoffrey Gillespie for leading the team as Interim CFO. I am excited to work with the talented finance and leadership teams as we look for opportunities to improve our performance while accelerating our business.'

Industry Context

The appointment of a seasoned CFO like Julie Andrews, with extensive experience in the medical device sector, aligns with the industry's focus on financial stability and strategic growth. Her previous roles at Wright Medical and Medtronic suggest a strong understanding of the market and its challenges.

Comparison to Industry Standards

• The inducement package provided to Ms. Andrews, including stock options and restricted stock units, is consistent with industry practices for attracting top-tier executive talent.
• The severance agreement, including cash payments, COBRA reimbursements, and accelerated vesting of equity awards, is comparable to those offered to CFOs at similar publicly traded medical device companies.
• The vesting schedules for the equity awards, with performance-based and time-based components, are also in line with industry standards for aligning executive compensation with company performance and long-term value creation.
• Companies such as Stryker and Medtronic, where Ms. Andrews previously worked, are known for offering competitive compensation packages to their executives, and Orthofix's offer appears to be in the same range.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially leading to increased confidence in the company's financial management and strategic direction.
• Employees may be impacted by the change in leadership within the finance department, but the appointment of a seasoned executive could be seen as a positive development.
• Customers and suppliers are unlikely to be directly impacted by this change, but a strong financial team can contribute to the company's overall stability and performance.

Next Steps

• Ms. Andrews will assume her role as CFO and begin working with the finance and leadership teams.
• The company will continue to focus on developing growth opportunities and improving performance.
• The company will monitor the performance of the stock options and restricted stock units granted to Ms. Andrews.

Key Dates

Keywords

Chief Financial Officer, CFO, Orthofix, Julie Andrews, executive appointment, severance agreement, stock options, restricted stock units, medical device, inducement plan